Log In
Print
BCIQ
Print
Print this Print this
 

cerium nitrate/silver sulfadiazine (Flammacerium)

  Manage Alerts
Collapse Summary General Information
Company Sinclair IS Pharma plc
DescriptionCream containing 1% silver sulfadiazine and 2.2% cerium nitrate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard Indication Infectious (unspecified)
Indication DetailsTreat and prevent infections in burn wounds
Regulatory Designation

U.S. - Orphan Drug (Treat and prevent infections in burn wounds)

Partner

Hikma Pharmaceuticals plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today